WO2018188612A1 - Anticorps bispécifique pouvant être combiné avec cd19 humain ou cd20 humain et cd3 humain, et applications associées - Google Patents
Anticorps bispécifique pouvant être combiné avec cd19 humain ou cd20 humain et cd3 humain, et applications associées Download PDFInfo
- Publication number
- WO2018188612A1 WO2018188612A1 PCT/CN2018/082692 CN2018082692W WO2018188612A1 WO 2018188612 A1 WO2018188612 A1 WO 2018188612A1 CN 2018082692 W CN2018082692 W CN 2018082692W WO 2018188612 A1 WO2018188612 A1 WO 2018188612A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- domain
- bispecific antibody
- combination
- antibody
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne un anticorps bispécifique pouvant être combiné avec CD19 humain ou CD20 humain et CD3 humain, destiné à être utilisé dans le traitement de maladies associées à la détérioration de cellules B.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710236421.8 | 2017-04-12 | ||
CN201710236421.8A CN108690138A (zh) | 2017-04-12 | 2017-04-12 | 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018188612A1 true WO2018188612A1 (fr) | 2018-10-18 |
Family
ID=63792298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/082692 WO2018188612A1 (fr) | 2017-04-12 | 2018-04-11 | Anticorps bispécifique pouvant être combiné avec cd19 humain ou cd20 humain et cd3 humain, et applications associées |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108690138A (fr) |
WO (1) | WO2018188612A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020135335A1 (fr) * | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Protéines multispécifiques de liaison à l'antigène pouvant se lier à cd19 et cd3, et leur utilisation |
US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
US11013800B2 (en) | 2011-05-16 | 2021-05-25 | Evive Biotech Ltd. | Multi-specific Fab fusion proteins comprising a CD3-binding Fab fragment with N-terminal fusion to binding domains and methods of use |
WO2022165171A1 (fr) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions et méthodes de traitement du syndrome de libération de cytokines |
WO2023201226A1 (fr) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions et méthodes permettant la destruction de cellule tumorale universelle |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109836502B (zh) * | 2018-11-12 | 2021-09-07 | 浙江大学 | 一种双特异性抗体及其应用 |
EP3897719A4 (fr) * | 2018-12-21 | 2022-11-02 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Anticorps bispécifiques clivables par la protéase et utilisations associées |
CN109776683B (zh) * | 2019-03-19 | 2020-04-07 | 益科思特(北京)医药科技发展有限公司 | 一种双特异性抗体及其制备方法与应用 |
CN116987197A (zh) * | 2019-06-20 | 2023-11-03 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
CN114685658A (zh) * | 2020-12-30 | 2022-07-01 | 百力司康生物医药(杭州)有限公司 | Ox40的靶向抗体及其制备方法和应用 |
CN115490770A (zh) * | 2021-06-17 | 2022-12-20 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人eta和人cd3结合的双特异性抗体及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1867586A (zh) * | 2003-10-16 | 2006-11-22 | 麦克罗梅特股份公司 | 多特异性的去免疫化cd3结合物 |
CN104356241A (zh) * | 2003-08-01 | 2015-02-18 | 美国政府(由卫生和人类服务部、国立卫生研究院的部长所代表) | 免疫毒素的表达和纯化方法 |
US20150218217A1 (en) * | 2014-01-31 | 2015-08-06 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
CN105530959A (zh) * | 2013-03-15 | 2016-04-27 | 纪念斯隆-凯特琳癌症中心 | 多聚化技术 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
JP4124480B2 (ja) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
WO1994012520A1 (fr) * | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Segment de liaison pour polypeptides fusionnes lies |
EA016429B1 (ru) * | 2005-12-30 | 2012-04-30 | Мерк Патент Гмбх | Антитела против cd19 с пониженной иммуногенностью |
AU2008260498B2 (en) * | 2007-05-30 | 2012-11-29 | Xencor, Inc. | Methods and compositions for inhibiting CD32b expressing cells |
CA2725666A1 (fr) * | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Immunoglobulines a double domaine variable et leurs utilisations |
US8815242B2 (en) * | 2009-05-27 | 2014-08-26 | Synageva Biopharma Corp. | Avian derived antibodies |
US9458246B2 (en) * | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
WO2015013671A1 (fr) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Anticorps multispécifiques, anticorps activables multispécifiques et leurs méthodes d'utilisation |
CN104592393B (zh) * | 2015-01-21 | 2018-09-28 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体cd19×cd3的构建及应用 |
CN104558191B (zh) * | 2015-01-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体cd20×cd3的构建及应用 |
WO2016154621A1 (fr) * | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | Récepteurs chimériques non-scfv commutables, commutateurs, et leurs utilisations |
-
2017
- 2017-04-12 CN CN201710236421.8A patent/CN108690138A/zh active Pending
-
2018
- 2018-04-11 WO PCT/CN2018/082692 patent/WO2018188612A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104356241A (zh) * | 2003-08-01 | 2015-02-18 | 美国政府(由卫生和人类服务部、国立卫生研究院的部长所代表) | 免疫毒素的表达和纯化方法 |
CN1867586A (zh) * | 2003-10-16 | 2006-11-22 | 麦克罗梅特股份公司 | 多特异性的去免疫化cd3结合物 |
CN105530959A (zh) * | 2013-03-15 | 2016-04-27 | 纪念斯隆-凯特琳癌症中心 | 多聚化技术 |
US20150218217A1 (en) * | 2014-01-31 | 2015-08-06 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11013800B2 (en) | 2011-05-16 | 2021-05-25 | Evive Biotech Ltd. | Multi-specific Fab fusion proteins comprising a CD3-binding Fab fragment with N-terminal fusion to binding domains and methods of use |
US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
WO2020135335A1 (fr) * | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Protéines multispécifiques de liaison à l'antigène pouvant se lier à cd19 et cd3, et leur utilisation |
WO2022165171A1 (fr) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions et méthodes de traitement du syndrome de libération de cytokines |
WO2023201226A1 (fr) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions et méthodes permettant la destruction de cellule tumorale universelle |
Also Published As
Publication number | Publication date |
---|---|
CN108690138A (zh) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018188612A1 (fr) | Anticorps bispécifique pouvant être combiné avec cd19 humain ou cd20 humain et cd3 humain, et applications associées | |
US20210301028A1 (en) | Composition and methods for anti-tnfr2 antibodies | |
JP6060073B2 (ja) | Cd122に対する抗体 | |
KR20190028534A (ko) | 항 gprc5d 항체, gprc5d 및 cd3에 결합하는 이중특이성 항원 결합 분자, 및 이들의 용도 | |
JP6928971B2 (ja) | ヒトpd−1抗原とそのリガンドの結合を拮抗・阻害するモノクローナル抗体およびその製造方法と使用 | |
CN108409862B (zh) | I型干扰素受体抗体及其用途 | |
CN111848809A (zh) | 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途 | |
JP7093794B2 (ja) | 免疫関連障害のための抗体-サイトカイングラフト化タンパク質及び使用方法 | |
JP2023106392A (ja) | Cd3抗原結合性断片及びその使用 | |
TW201522373A (zh) | 抗cd52之抗體 | |
CN112521501A (zh) | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 | |
US20230235073A1 (en) | Anti-cd36 antibodies and their use to treat cancer | |
KR20200133365A (ko) | Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용 | |
CN113166239B (zh) | 抗il-17a抗体及其应用 | |
CN110357959B (zh) | Gcgr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 | |
CN114437212B (zh) | 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用 | |
CN112313250A (zh) | 结合cd38的变体抗体 | |
WO2006121159A1 (fr) | Anticorps humanise greffe en cdr reagissant specifiquement avec cd10 et le fragment d’anticorps de celui-ci | |
TW202112813A (zh) | 對lif具有專一性的結合分子及其用途 | |
EP3808847A1 (fr) | Anticorps apj, protéine de fusion de celui-ci avec elabela, et compositions pharmaceutiques et utilisation associées | |
WO2022262733A1 (fr) | Anticorps bispécifique capable de se lier à l'eta humain et au cd3 humain et son application | |
TWI814094B (zh) | 貓抗體變異體 | |
WO2022247826A1 (fr) | Protéine de liaison spécifique ciblant pd-l1 et cd73 | |
RU2800370C2 (ru) | Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение | |
WO2022206857A1 (fr) | Anticorps capable de se lier spécifiquement au récepteur de l'endothéline humain, et son utilisation dans le traitement d'une néphropathie diabétique et d'une néphropathie chronique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18785179 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18785179 Country of ref document: EP Kind code of ref document: A1 |